NDA 217900 · Sun Pharm Inds INC
Leqselvi
Deuruxolitinib Phosphate · Oral
NovelCDER novel approval, Jul 25, 2024: To treat severe alopecia areata
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 25, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 2 recruiting
FAERS reports
174
5 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS Increased risk of serious bacterial, fungal, viral and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death. Interrupt treatment with LEQSELVI if a serious infection occurs until the infection is controlled. LEQSELVI treatment is not recommended in patients with active tuberculosis. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ) Higher rate of all-cause mortality, including sudden cardiovascular death, was observed with another Janus kinase (JAK) inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. LEQSELVI is not approved for use in RA patients. ( 5.2 ) Malignancies were reported in...
What it is approved for
From the label in effect Sep 28, 2026.
LEQSELVI ® is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. LEQSELVI is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata. ( 1 ) Limitations of Use: LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1 )
Mechanism: Deuruxolitinib is a Janus kinase (JAK) inhibitor. JAKs mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. In an in vitro kinase activity assay, deuruxolitinib had greater inhibitory potency for JAK1, JAK2 and TYK2 relative to JAK3. The relevance of inhibition of JAK enzymes to therapeutic...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 25, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- LEQSELVI · DEURUXOLITINIB PHOSPHATE EQ 8MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Deuruxolitinib" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07133308 · 355 participants (planned) · Start Aug 5, 2025 · Primary completion May 2028
Drug: Deuruxolitinib; Placebo · For: Alopecia Areata
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bryant, Arkansas · 64 sites in all
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataPivotal-lookingRecruiting
Sun Pharma Japan LimitedIndustry
NCT07617597 · 78 participants (planned) · Start Jun 19, 2026 · Primary completion Feb 2028
Drug: Deuruxolitinib; Placebo · For: Alopecia Areata
Sites: Asahikawa, Japan; Bunkyō City, Japan; Ebina, Japan · 18 sites in all
Concert PharmaceuticalsIndustry
NCT05467722 · 21 participants · Start Jun 1, 2022 · Primary completion Sep 15, 2022
Drug: CTP-543 · For: Hepatic Impairment
Sites: Orlando, Florida; Knoxville, Tennessee
Concert PharmaceuticalsIndustry
NCT05468749 · 16 participants · Start Jun 6, 2022 · Primary completion Oct 20, 2022
Drug: CTP-543 · For: Renal Impairment
Sites: Orlando, Florida; Knoxville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use issue39
- drug ineffective28
- product dose omission issue20
- therapy cessation15
- fatigue11
- acne10
- headache7
- condition aggravated6
- intentional dose omission6
- nasopharyngitis6
- therapy interrupted6
- weight increased6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 12 |
| 2026 | 162 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
King B, Senna MM, Mesinkovska NA, et al. · J Am Acad Dermatol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis.
Martinez J, Manjaly C, Manjaly P, et al. · JAMA Dermatol 2023 · Meta-Analysis, Systematic Review
- Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.
Babul A, Mehta D, Soliman Y, et al. · J Dermatol 2026 · Network Meta-Analysis, Comparative Study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.
Tsianakas A, Passeron T, Magnolo N, et al. · J Am Acad Dermatol 2026 · Randomized Controlled Trial, Multicenter Study
- Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Krebs M, Gulyás L, Fazekas KK, et al. · J Eur Acad Dermatol Venereol 2026 · Meta-Analysis, Systematic Review
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.
Kalantan M, Bashrahil B, Aljuaid A, et al. · Front Med (Lausanne) 2025 · Systematic Review
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.